HA
NMRA icon

HHLR Advisors’s Neumora Therapeutics NMRA Stock Holding History

HHLR Advisors’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,699,313
Closed -$29M – 67
2023
Q4 		$29M Hold
1,699,313
– – 0.58% 21
2023
Q3 		$24M Buy
+1,699,313
New +$21.2M 0.54% 24

Other funds holding NMRA

SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

HHLR Advisors's NMRA Position: Q1 2024 in Review

HHLR Advisors sold out of Neumora Therapeutics (NMRA) in Q1 2024, closing a stake of 1,699,313 shares — an estimated $29M sold.

HHLR Advisors first reported a position in NMRA in Q3 2023 and held it in 2 quarters. The position peaked at $29M in Q4 2023. 88 funds tracked by Wall St. Rank hold NMRA as of Q1 2024.

  • HHLR Advisors reported no remaining Neumora Therapeutics position as of Q1 2024 after selling out during the quarter.
  • HHLR Advisors sold 1,699,313 Neumora Therapeutics shares in Q1 2024, an estimated $29M.
  • HHLR Advisors first reported a position in Neumora Therapeutics in Q3 2023 and held it in 2 quarters.
  • HHLR Advisors's Neumora Therapeutics position peaked at $29M in Q4 2023.
  • 88 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q1 2024.

Based on HHLR Advisors's 13F filing for Q1 2024, filed 14 May 2024.